Advertisement
Screener

TSCAN THERAPEUTICS, INC. (TCRX) Other Non-Current Liabilities

2.8 / 5 stars · 68/120 Roast Me

TSCAN THERAPEUTICS, INC. Other Non-Current Liabilities

TSCAN THERAPEUTICS, INC. (TCRX) had Other Non-Current Liabilities of $278.00 thousand as of 2025-09-30, per its 10-Q filed 2025-11-12.

Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent

us-gaap:OtherLiabilitiesNoncurrent · last filed 2026-03-04

  • 2025-09-30: Other Liabilities, Noncurrent $278.00K.
  • 2025-06-30: Other Liabilities, Noncurrent $113.00K.
  • 2025-03-31: Other Liabilities, Noncurrent $124.00K.
  • 2024-12-31: Other Liabilities, Noncurrent $135.00K.
Period endOther Liabilities, Noncurrent
2025-09-30$278.00K
10-Q · filed 2025-11-12
2025-06-30$113.00K
10-Q · filed 2025-08-12
2025-03-31$124.00K
10-Q · filed 2025-05-06
2024-12-31$135.00K
10-K · filed 2026-03-04
2024-09-30$146.00K
10-Q · filed 2024-11-12
2023-09-30$12.00K
10-Q · filed 2023-11-09
2023-06-30$24.00K
10-Q · filed 2023-08-10
2023-03-31$36.00K
10-Q · filed 2023-05-10
2022-12-31$49.00K
10-K · filed 2024-03-06
2022-09-30$97.00K
10-Q · filed 2022-11-09
2022-06-30$97.00K
10-Q · filed 2022-08-10
2022-03-31$97.00K
10-Q · filed 2022-05-12
2021-12-31$97.00K
10-K · filed 2023-03-08
2021-09-30$236.00K
10-Q · filed 2021-11-10
2021-06-30$238.00K
10-Q · filed 2021-08-19
2020-12-31$238.00K
10-K · filed 2022-03-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
CERO THERAPEUTICS HOLDINGS, INC. (CERO)United States$0.007B
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B
AIM ImmunoTech Inc. (AIM)United States$0.006B
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
IN8BIO, INC. (INAB)United States$0.012B-0.76
PharmaCyte Biotech, Inc. (PMCB)United States$0.005B
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)United States$0.013B-1.05
INTENSITY THERAPEUTICS, INC. (INTS)United States$0.013B-1.08
WINDTREE THERAPEUTICS INC /DE/ (WINT)United States$0.003B-0.32
VivoSim Labs, INC. (VIVS)United States$0.003B